Wednesday, September 4, 2024, Houston, Texas, 11:46 AM – 12:46 PM Central Time (12:46 PM – 1:46 PM Eastern Time)
Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Part 1 of a 2-Part CME Satellite Symposium Series During the Society of Hematologic Oncology 2024 Annual Meeting
Event Details
Wednesday, September 4, 2024
11:46 AM – 12:46 PM Central Time
Educational Lunch Meeting
Location
George R Brown Convention Center
1001 Avenida de las Americas
Houston, Texas
Phone: (713) 853-8000
Meeting Room
Level 3 in Grand Ballroom C (Theater 2)
This event will also be webcast live.
Please see Registration tab for details.
Joshua Brody, MD
Director, Lymphoma Immunotherapy Program
The Tisch Cancer Institute at Mount Sinai
Faculty Member, Icahn Genomics Institute
Icahn School of Medicine at Mount Sinai
New York, New York
Jason Westin, MD, MS
Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
Professor, Department of Lymphoma and Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Matthew Lunning, DO
Associate Professor of Medicine
Medical Director, Cellular Therapy
Associate Vice Chair of Research
Assistant Vice Chancellor for Clinical Research
Division of Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska
This CE activity is supported through educational grants from Bristol Myers Squibb and Novartis.
Agenda
Wednesday, September 4, 2024
11:46 AM – 12:46 PM Central Time
Educational Lunch Meeting
MODULE 1: Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Diffuse Large B-Cell Lymphoma (DLBCL)
- Major findings from Phase III studies with CAR T-cell therapy as second-line treatment for DLBCL
- FDA approvals of axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) as second-line therapy and appropriate identification of candidates for this strategy
- Long-term efficacy and safety data with axi-cel, liso-cel and tisagenlecleucel (tis-cel) for multiregimen-relapsed DLBCL
- Rationale for the evaluation of CAR T-cell therapy in the up-front setting; key results from the ZUMA-12 study evaluating axi-cel as first-line therapy for patients with high-risk disease
- Early results with and ongoing evaluation of other novel CAR T-cell platforms for DLBCL
MODULE 2: Current Role of CAR T-Cell Therapy for Other B-Cell Lymphomas
- Principal outcomes with axi-cel, tis-cel and liso-cel for relapsed/refractory (R/R) follicular lymphoma (FL)
- Selection of appropriate candidates with R/R FL for CAR T-cell therapy
- Key clinical research findings with brexucabtagene autoleucel and liso-cel for R/R mantle cell lymphoma (MCL)
- Optimal integration of CAR T-cell therapy into current MCL treatment
- Published findings with liso-cel for R/R chronic lymphocytic leukemia (CLL) from the Phase I/II TRANSCEND CLL 004 trial; rates of complete response compared to historical controls
- FDA accelerated approval of liso-cel for CLL previously treated with a Bruton tyrosine kinase inhibitor and a Bcl-2 inhibitor; current clinical role
MODULE 3: Tolerability and Other Practical Considerations with CAR T-Cell Therapy
- Comparative incidence and severity of cytokine release syndrome and neurotoxicity with available anti-CD19 CAR T-cell constructs in various non-Hodgkin lymphoma subtypes; optimal monitoring and management
- Long-term tolerability/toxicity considerations (eg, delayed neurotoxicity, cytopenias, hypogammaglobulinemia, infection) with CAR T-cell therapy
- Recent FDA boxed warning requirement for the risk of T-cell malignancies in patients who have received CAR T-cell therapy
- Potential effect of prior therapeutic exposure on the antitumor activity of CAR T-cell therapy
- Proportion of patients achieving long-term remissions after CAR T-cell therapy; appropriateness of discussing the possibility of “cure”
CE Information
Target Audience
This activity is intended for hematologists, hematology-oncology fellows, medical oncologists and other healthcare providers involved in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Learning Objectives
Upon completion of this activity, participants should be able to
- Develop an understanding of the scientific rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with various forms of lymphoma.
- Appreciate long-term efficacy and safety data with FDA-approved CAR T-cell therapies directed at CD19 in multiregimen-relapsed diffuse large B-cell lymphoma (DLBCL).
- Identify patients with DLBCL and relapse on first-line therapy for whom treatment with CAR T-cell therapy would be appropriate.
- Evaluate published research findings to determine the current clinical role of CAR T-cell therapy for patients with other B-cell lymphomas, including mantle cell lymphoma and follicular lymphoma.
- Appreciate available data documenting the activity of CAR T-cell therapy in patients with relapsed/refractory chronic lymphocytic leukemia.
- Implement strategies to educate patients eligible for treatment with CD19-directed CAR T-cell therapy about the potential for short- and long-term complications.
CE Credit
A CME credit link will be given to each participant at the conclusion of the activity.
Accreditation, Support and Credit Statements
In support of improving patient care, Medical Learning Institute, Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support Statement
This CE activity is supported through educational grants from Bristol Myers Squibb and Novartis.
Physician Continuing Medical Education
Medical Learning Institute, Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure and Conflict of Interest Policy
Medical Learning Institute, Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy.
FACULTY — Dr Brody has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Westin — Consulting Agreements: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Novartis, Nurix Therapeutics Inc, Pfizer Inc.
MODERATOR — Dr Lunning — Consulting Honoraria: AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, CRISPR Therapeutics, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Recordati, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Vittoria Biotherapeutics; Research Funding: Bristol Myers Squibb, Fate Therapeutics, Sana Biotechnology.
Planning Committee and Content/Peer Reviewers — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This symposium is planned and provided by Medical Learning Institute, Inc and Research To Practice. This accredited CE activity is an independent satellite symposium in conjunction with the Society of Hematologic Oncology 2024 Annual Meeting and is supported by Bristol Myers Squibb and Novartis.
Location
George R Brown Convention Center
1001 Avenida de las Americas
Houston, TX 77010
Main Phone: (713) 853-8000
Meeting Room
Level 3 in Grand Ballroom C (Theater 2)
Directions
The George R Brown Convention Center is the main venue for the SOHO 2024 Annual Meeting.
Registration
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in Houston, you must also be registered to attend the SOHO 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program.
Our onsite registration desk will be open at 11:30 AM central time on Wednesday, September 4th. If you are interested in attending, please visit our registration desk outside Level 3 in Grand Ballroom C (Theater 2) at the George R Brown Convention Center.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
REGISTRATION FOR WEBCAST »Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.